Mandate

Vinge advises Xspray Pharma in connection with a directed share issue

December 10, 2019 Capital Markets and Public M&A

Vinge has advised the pharmaceutical development company Xspray Pharma in connection with a directed share issue, whereby Xspray receives proceeds of approximately SEK 122 million.

The share issue was directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process. The purpose of the share issue is to raise capital for the continued development of projects and to strengthen the company’s shareholder base.

Vinge’s team has consisted of Dain Hård Nevonen, Nils Fredrik Dehlin and Joel Magnusson.

Related

Vinge advises Qben Infra in connection with issuance of senior, unsecured bonds and early redemption

Vinge has advised Qben Infra AB in connection with its issuance of senior, unsecured bonds in an amount of SEK 500,000,000 (within a framework of SEK 600,000,000) and the parallel early redemption by its subsidiary ININ Group AS in respect of its previously issued senior secured bonds due 2027.
January 16, 2025

Vinge advises Intera Partners in connection with the investment in Yellow Elk

Vinge has advised the Nordic private equity firm Intera Partners in connection with its investment in the AI and data analytics firm Yellow Elk.
January 15, 2025

Vinge has represented Inflexion in connection with the acquisition of Mecenat

Vinge has represented Inflexion in connection with the acquisition of the Mecenat group from IK. The acquisition of Mecenat is the first investment made through Inflexion's new Enterprise Fund VI, and Inflexion's first acquisition in Sweden.
January 14, 2025